Results 101 to 110 of about 18,508 (192)

Highlights from the 9th IAS conference on HIV science, 23-26 July 2017, Paris, France [PDF]

, 2017
The 9th International AIDS Society Conference on HIV Science (IAS 2017) took place at the Palais des Congrès, in Paris, France, from 23 to 26 July 2017, chaired by Linda-Gail Bekker and Jean-François Delfraissy. It was organised by the International AIDS
Barber, Tristan J, Kinloch-de Loës, Sabine, Psomas, Christina K, Rutsaert, Sofie   +3 more
core   +2 more sources

Potential benefit of dolutegravir once daily: efficacy and safety

HIV/AIDS: Research and Palliative Care, 2013
Alessandra Fantauzzi,1 Ombretta Turriziani,2 Ivano Mezzaroma11Department of Clinical Medicine, 2Department of Molecular Medicine, Sapienza, University of Rome, Rome, ItalyAbstract: The viral integrase enzyme has recently emerged as a primary alternative ...
Fantauzzi A, Turriziani O, Mezzaroma I
doaj  

Rapid onset of hypercalcemia from high-grade lymphoma in the setting of HIV-related immune reconstitution inflammatory syndrome. [PDF]

, 2019
Hypercalcemia in HIV patients has been previously reported, but 1,25-(OH)2 vitamin D-mediated hypercalcemia, due to increased activity of extrarenal 1-alpha hydroxylase, is rarely described with HIV-related infections or malignancies.
Bikle, Daniel, Kim, Sarah, Kim, Stephanie J, Peluso, Michael J, Shoback, Dolores, Wang, Yongmei   +5 more
core  

Lancet HIV [PDF]

BackgroundThere is concern over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in people initiating antiretroviral therapy (ART) in low-income and middle-income countries. We assessed the effectiveness and cost-

core  

Brief communication: Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya, Tanzania

AIDS Research and Therapy
Background The World Health Organization recommends dolutegravir-based antiretroviral therapy (ART) as the preferred first-line regimen for HIV treatment.
Revocatus T. Majula, Clement N. Mweya
doaj   +1 more source

¿La combinación dolutegravir y rifampicina en los pacientes no incluidos en los ensayos clínicos es también eficaz y segura en el binomio VIH-infección micobacteriana? Casos de la práctica clínica

Medicina Clínica Práctica
Resumen: Introducción: las infecciones micobacterianas (IM) y la infección por VIH (iVIH) siguen siendo un binomio frecuente. La rifampicina dificulta el uso de los antirretrovirales.
Sara Fontserè Recuenco, Rafael Luque-Márquez   +1 more
doaj   +1 more source

Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women

CPT: Pharmacometrics & Systems Pharmacology
Optimal dosing in pregnant and lactating women requires an understanding of the pharmacokinetics in the mother, fetus, and breastfed infant. Physiologically‐based pharmacokinetic (PBPK) modeling can be used to simulate untested scenarios and hence ...
Jia Ning, Amita Pansari, Karen Rowland Yeo, Aki T. Heikkinen, Catriona Waitt, Lisa M. Almond   +5 more
doaj   +1 more source

A review of dolutegravir-associated weight gain and secondary metabolic comorbidities

SAGE Open Medicine
Dolutegravir is an integrase inhibitor and is recommended by the World Health Organization as the preferred first-line and second-line human immunodeficiency virus treatment in all populations.
Mohammed Jemal
doaj   +1 more source

Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing [PDF]

, 2016
Chaponda, Mas, Khoo, Saye, Lewis, Joseph M, Railton, Eimear, Riordan, Andrew   +4 more
core   +1 more source

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake [PDF]

, 2015
Amara, Alieu, Back, David, Boffito, Marta, Elliot, Emilie, Else, Laura, Jackson, Akil, Khoo, Saye, Moyle, Graeme, Owen, Andrew   +8 more
core   +1 more source